Telmisartan improves cardiac fibrosis in diabetes through peroxisome proliferator activated receptor δ (PPARδ): From bedside to bench

Cardiovascular Diabetology

Volumn 15, Issue 1, 2016, Pages

  Chang, Wei Ting ^a   Cheng, Juei Tang ^a   Chen, Zhih Cherng ^a,b  

^a CHI MEI MEDICAL CENTER   (Taiwan)

^b CHIA NAN UNIVERSITY OF PHARMACY AND SCIENCE   (Taiwan)

Author keywords

Diabetic cardiomyopathy; PPAR ; STAT3; Telmisartan

Indexed keywords

METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; STAT3 PROTEIN; TELMISARTAN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BENZIMIDAZOLE DERIVATIVE; BENZOIC ACID DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; STAT3 PROTEIN, RAT; STREPTOZOCIN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIAC MUSCLE CELL; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG MECHANISM; FEMALE; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HEART MUSCLE FIBROSIS; HEART VENTRICLE REMODELING; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; LONGITUDINAL STUDY; MALE; NONHUMAN; PROSPECTIVE STUDY; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; RAT; SIGNAL TRANSDUCTION; SPECKLE TRACKING ECHOCARDIOGRAPHY; UPREGULATION; ANIMAL; CARDIAC MUSCLE; CELL LINE; CONTROLLED CLINICAL TRIAL; DIABETES MELLITUS, TYPE 1; DIABETIC CARDIOMYOPATHIES; DRUG EFFECTS; EXPERIMENTAL DIABETES MELLITUS; FIBROSIS; HEART LEFT VENTRICLE FUNCTION; METABOLISM; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; SPRAGUE DAWLEY RAT; TIME FACTOR; TRANSLATIONAL RESEARCH; TREATMENT OUTCOME;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BENZIMIDAZOLES; BENZOATES; CELL LINE; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DIABETIC CARDIOMYOPATHIES; FEMALE; FIBROSIS; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MYOCARDIUM; MYOCYTES, CARDIAC; PPAR GAMMA; PROSPECTIVE STUDIES; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; STREPTOZOCIN; TIME FACTORS; TRANSLATIONAL MEDICAL RESEARCH; TREATMENT OUTCOME; UP-REGULATION; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 85007463575     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/s12933-016-0430-5     Document Type: Article

References (41)

1. Boudina S, Abel ED. Diabetic cardiomyopathy revisited. Circulation. 2007;115(25):3213-23.
2. Mochizuki Y, Tanaka H, Matsumoto K, et al. Clinical features of subclinical left ventricular systolic dysfunction in patients with diabetes mellitus. Cardiovasc Diabetol. 2015;14:37.
3. Mor-Avi V, Lang RM, Badano LP, et al. Current and evolving echocardiographic techniques for the quantitative evaluation of cardiac mechanics: ASE/EAE consensus statement on methodology and indications endorsed by the Japanese Society of Echocardiography. J Am Soc Echocardiogr. 2011;24(3):277-313.
4. Maejima Y, Okada H, Haraguchi G, et al. Telmisartan, a unique ARB, improves left ventricular remodeling of infarcted heart by activating PPAR gamma. Lab Invest. 2011;91(6):932-44.
5. Chang CH, Chang YC, Wu LC, Lin JW, Chuang LM, Lai MS. Different angiotensin receptor blockers and incidence of diabetes: a nationwide population-based cohort study. Cardiovasc Diabetol. 2014;13:91.
6. Wang WW, Zhang FL, Chen JH, et al. Telmisartan reduces atrial arrhythmia susceptibility through the regulation of RAS-ERK and PI3 K-Akt-eNOS pathways in spontaneously hypertensive rats. Can J Physiol Pharmacol. 2015;93(8):657-65.
7. Dessi M, Madeddu C, Piras A, et al. Long-term, up to 18 months, protective effects of the angiotensin II receptor blocker telmisartan on Epirubininduced inflammation and oxidative stress assessed by serial strain rate. Springerplus. 2013;2(1):198.
8. Mizuguchi Y, Oishi Y, Miyoshi H, Iuchi A, Nagase N, Oki T. Beneficial effects of telmisartan on left ventricular structure and function in patients with hypertension determined by two-dimensional strain imaging. J Hypertens. 2009;27(9):1892-9.
9. Zeng XC, Li XS, Wen H. Telmisartan protects against microvascular dysfunction during myocardial ischemia/reperfusion injury by activation of peroxisome proliferator-activated receptor gamma. BMC Cardiovasc Disord. 2013;5(13):39.
10. Sukumaran V, Watanabe K, Veeraveedu PT, et al. Telmisartan, an angiotensin-II receptor blocker ameliorates cardiac remodeling in rats with dilated cardiomyopathy. Hypertens Res. 2010;33(7):695-702.
11. Kawai M, Hongo K, Komukai K, et al. Telmisartan predominantly suppresses cardiac fibrosis, rather than hypertrophy, in renovascular hypertensive rats. Hypertens Res. 2009;32(7):604-10.
12. Goyal S, Arora S, Mittal R, et al. Myocardial salvaging effect of telmisartan in experimental model of myocardial infarction. Eur J Pharmacol. 2009;619(1-3):75-84.
13. Calkin AC, Thomas MC. PPAR agonists and cardiovascular disease in diabetes. PPAR Res. 2008;2008:245410.
14. Chen ZC, Lee KS, Chen LJ, Wang LY, Niu HS, Cheng JT. Cardiac peroxisome proliferator-activated receptor delta (PPARdelta) as a new target for increased contractility without altering heart rate. PLoS ONE. 2013;8(5):e64229.
15. Wilding JP. PPAR agonists for the treatment of cardiovascular disease in patients with diabetes. Diabetes Obes Metab. 2012;14(11):973-82.
16. Yu BC, Chang CK, Ou HY, Cheng KC, Cheng JT. Decrease of peroxisome proliferator-activated receptor delta expression in cardiomyopathy of streptozotocin-induced diabetic rats. Cardiovasc Res. 2008;80(1):78-87.
17. Zhang W, Qu X, Chen B, et al. Critical roles of STAT3 in β-adrenergic functions in the heart. Circulation. 2016;133(1):48-61.
18. Serrano-Marco L, Barroso E, El Kochairi I, et al. The peroxisome proliferator-activated receptor (PPAR) beta/delta agonist GW501516 inhibits IL-6-induced signal transducer and activator of transcription 3 (STAT3) activation and insulin resistance in human liver cells. Diabetologia. 2012;55:743-51.
19. Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28(1):1-39.
20. Pitt B, Zannad F. The detection of myocardial fibrosis: an opportunity to reduce cardiovascular risk in patients with diabetes mellitus? Circ Cardiovasc Imaging. 2012;5(1):9-11.
21. Halade GV, Jin YF, Lindsey ML. Matrix metalloproteinase (MMP)-9: a proximal biomarker for cardiac remodeling and a distal biomarker for inflammation. Pharmacol Ther. 2013;139(1):32-40.
22. Oyamada S, Bianchi C, Takai S, Chu LM, Sellke FW. Chymase inhibition reduces infarction and matrix metalloproteinase-9 activation and attenuates inflammation and fibrosis after acute myocardial ischemia/reperfusion. J Pharmacol Exp Ther. 2011;339(1):143-51.
23. Palomer X, Salvado L, Barroso E, Vazquez-Carrera M. An overview of the crosstalk between inflammatory processes and metabolic dysregulation during diabetic cardiomyopathy. Int J Cardiol. 2013;168(4):3160-72.
24. Mikami D, Kimura H, Kamiyama K, et al. Telmisartan activates endogenous peroxisome proliferator-activated receptor-delta and may have anti-fibrotic effects in human mesangial cells. Hypertens Res. 2014;37(5):422-31.
25. Feng X, Luo Z, Ma L, et al. Angiotensin II receptor blocker telmisartan enhances running endurance of skeletal muscle through activation of the PPAR-delta/AMPK pathway. J Cell Mol Med. 2011;15(7):1572-81.
26. Li L, Luo Z, Yu H, et al. Telmisartan improves insulin resistance of skeletal muscle through peroxisome proliferator-activated receptor-delta activation. Diabetes. 2013;62(3):762-74.
27. Serrano-Marco L, Rodriguez-Calvo R, El Kochairi I, et al. Activation of peroxisome proliferator-activated receptor-beta/-delta (PPAR-beta/-delta) ameliorates insulin signaling and reduces SOCS3 levels by inhibiting STAT3 in interleukin-6-stimulated adipocytes. Diabetes. 2011;60(7):1990-9.
28. Cheng JT, Huang CC, Liu IM, Tzeng TF, Chang CJ. Novel mechanism for plasma glucose-lowering action of metformin in streptozotocin-induced diabetic rats. Diabetes. 2006;55(3):819-25.
29. Pesant M, Sueur S, Dutartre P, et al. Peroxisome proliferator-activated receptor delta (PPARdelta) activation protects H9c2 cardiomyoblasts from oxidative stress-induced apoptosis. Cardiovasc Res. 2006;69(2):440-9.
30. Haghikia A, Ricke-Hoch M, Stapel B, Gorst I, Hilfiker-Kleiner D. STAT3, a key regulator of cell-to-cell communication in the heart. Cardiovasc Res. 2014;102(2):281-9.
31. Jacoby JJ, Kalinowski A, Liu MG, et al. Cardiomyocyte-restricted knockout of STAT3 results in higher sensitivity to inflammation, cardiac fibrosis, and heart failure with advanced age. Proc Natl Acad Sci USA. 2003;100(22):12929-34.
32. Li Y, Zhang H, Liao W, et al. Transactivated EGFR mediates alpha(1)-ARinduced STAT3 activation and cardiac hypertrophy. Am J Physiol Heart Circ Physiol. 2011;301(5):H1941-51.
33. Mashili F, Chibalin AV, Krook A, Zierath JR. Constitutive STAT3 phosphorylation contributes to skeletal muscle insulin resistance in type 2 diabetes. Diabetes. 2013;62(2):457-65.
34. Das A, Salloum FN, Filippone SM, et al. Inhibition of mammalian target of rapamycin protects against reperfusion injury in diabetic heart through STAT3 signaling. Basic Res Cardiol. 2015;110(3):31.
35. Benson SC, Pershadsingh HA, Ho CI, et al. Identification of telmisartan as a unique angiotensin ii receptor antagonist with selective ppargammamodulating activity. Hypertension. 2004;43(5):993-1002.
36. Janke J, Schupp M, Engeli S, et al. Angiotensin type 1 receptor antagonists induce human in vitro adipogenesis through peroxisome proliferator-activated receptor-gamma activation. J Hypertens. 2006;24(9):1809-16.
37. Kusunoki H, Taniyama Y, Rakugi H, Morishita R. Cardiac and renal protective effects of irbesartan via peroxisome proliferator-activated receptorgamma-hepatocyte growth factor pathway independent of angiotensin ii type 1a receptor blockade in mouse model of salt-sensitive hypertension. J Am Heart Assoc. 2013;2(2):e000103.
38. Nagashima A, Watanabe R, Ogawa M, et al. Different roles of PPAR-γ activity on physiological and pathological alteration after myocardial ischemia. J Cardiovasc Pharmacol. 2012;60(2):158-64.
39. Liu HJ, Liao HH, Yang Z, Tang QZ. Peroxisome proliferator-activated receptor-γ is critical to cardiac fibrosis. PPAR Res. 2016;2016:2198645.
40. Beltowski J, Rachanczyk J, Wlodarczyk M. Thiazolidinedioneinduced fluid retention: recent insights into the molecular mechanisms. PPAR Res. 2013;2013:628628.
41. Li H, Liu Z, Wang J, et al. Susceptibility to myocardial ischemia reperfusion injury at early stage of type 1 diabetes in rats. Cardiovasc Diabetol. 2013;12:133.